- Pharyngoconjunctival Fever (PCF), a contagious viral eye and respiratory infection often caused by adenovirus, is becoming an increasing concern in both developed and developing healthcare settings due to its high transmissibility in schools, hospitals, and military institutions. Rising awareness about infection control and improved diagnostic accessibility is aiding market expansion for PCF-related diagnostic and treatment solutions
- The growing demand for early viral detection, combined with heightened hygiene awareness post-COVID-19, is a major factor driving investments in diagnostic kits and public health programs aimed at controlling PCF outbreaks, particularly in densely populated regions
- North America dominated the pharyngoconjunctival fever market with the largest revenue share of 38.7% in 2024, attributed to advanced healthcare infrastructure, strong government screening initiatives, and robust presence of diagnostic and pharmaceutical companies
- Asia-Pacific is expected to be the fastest-growing region in the pharyngoconjunctival fever market during the forecast period, with a projected CAGR of 9.2% from 2025 to 2032, driven by rapid urbanization, growing healthcare expenditure, and increased adoption of point-of-care viral diagnostic tools in countries such as China, India, and South Korea
- The Fever segment dominated the pharyngoconjunctival fever market with a market share of 38.6% in 2024, owing to its common presence as the primary symptom that prompts medical consultation and testing. The widespread occurrence of fever in early stages of infection has made it a critical focus for early diagnosis and supportive care, especially in pediatric and institutional settings where viral spread is rapid
